Sana Biotechnology (SANA) Change in Accured Expenses (2020 - 2026)

Sana Biotechnology has reported Change in Accured Expenses for 7 years, with the latest figure at -$7.1 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 20.23% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.9 million (up 60.63% YoY) and the FY2025 annual result came in at -$4.7 million, up 43.54% from the prior year.
• Change in Accured Expenses slipped to -$7.1 million in Q1 2026 per SANA's latest filing, from $5.8 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $7.9 million in Q3 2022 and troughed at -$10.3 million in Q1 2023.
• A 5-year average of -$637000.0 and a median of $167000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 1913.17% in 2024, then jumped 304.56% in 2025.
• Over 5 years, Change in Accured Expenses stood at $2.1 million in 2022, then plunged by 91.96% to $167000.0 in 2023, then tumbled by 1913.17% to -$3.0 million in 2024, then jumped by 290.13% to $5.8 million in 2025, then slumped by 223.22% to -$7.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$7.1 million, $5.8 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.